JianYiBao Secures Tens of Millions in Series A+ Funding to Expand Risk and Health Management Platform for Patients with Pre-existing Conditions

Recently, Beijing Jianyibao Technology Co., Ltd. officially announced the completion of its tens-of-millions-yuan Series A+ financing round, led by China Zhongji Investment Corporation Limited and followed by For Future Equity Investment Management (Guangzhou) Co., Ltd. According to reports, the funds raised in this round will be primarily used to further strengthen the company’s core business and expand its patient channels across China. Previously, Jianyibao had secured three rounds of financing within less than two years from investors including Puhua Capital and Baidu Venture Capital.

It is understood that Jianyibao, established in 2017 in Beijing, is China’s first comprehensive service platform systematically dedicated to risk and health management for individuals with pre-existing conditions. Jianyibao has successfully linked pharmaceutical companies, medication usage scenarios, and financial insurance institutions. Addressing the cross-industry pain points of these three parties, and leveraging its core competencies in professionalism, technology, and innovation, Jianyibao collaborates with insurance companies to develop insurable products tailored for individuals with pre-existing conditions. This initiative aims to resolve health coverage challenges for this population, actively contribute to and participate in the construction of a multi-tiered medical security system, and promote the healthy development of society.

Since its inception, Jianyibao has successively launched commercial insurance products tailored for specific patient populations, including the “Xin Yi Bao” and “Xin Nao Yi Bao” coverage plans for patients with the “three highs” (hypertension, hyperglycemia, and hyperlipidemia), the “Jie Li Bao” coverage plan for patients with multiple sclerosis, and the Euthyrox Long-Term Cancer Insurance (available for post-operative thyroid cancer patients). These initiatives have achieved numerous industry firsts, improved the financial plight of hundreds of thousands of patients who were at risk of falling into or returning to poverty due to illness, and restored hope in their lives.

Wu Fushen, Partner and Managing Director of China Zhongji Investment Corporation Limited, stated that the investment in Jianyibao represents a strategic move by Zhongji Capital in the broader health sector, primarily for the following reasons:

First, the vast population market.China currently has nearly 500 million people with pre-existing conditions and 300 million individuals with chronic diseases. These groups are often the most urgent candidates for commercial insurance, yet traditional health insurance products struggle to meet their risk protection needs, leaving very few options available in the market for those with pre-existing conditions.

Second, the state’s encouragement of innovation in commercial health insurance.Both the launch of the “Tax-Advantaged Health Insurance” policy and the latest revision of the Measures for the Administration of Health Insurance underscore the state’s support for in-depth innovation in commercial health insurance.

Third, Jianyibao’s core competitiveness in professionalism, technology, and innovation.Although Jianyibao has been in operation for just over two years, the competitiveness demonstrated by its core team in product development and channel construction is impressive. The company has also partnered with insurance providers to launch several highly influential insurance products within the industry, bringing significant benefits to individuals with pre-existing conditions.

As a seasoned investor in the pharmaceutical and healthcare industry, Zhao Yang, Partner at For Future Capital, also acknowledged the vast scale of the niche health insurance market and strong government support. He stated, “Commercial health insurance products suffer from severe homogenization, limited sales scenarios, and a lack of innovative entry points. On the product side, there is a shortage of personalized, diversified, and customized insurance designs, resulting in high similarity among offerings from different companies. This homogenization leads to high exclusivity of products on the client side, which hinders the expansion of market capacity. Most insurance companies rely on traditional offline channels used for life and property insurance to sell health insurance; these channels are insufficiently specialized in health insurance, entailing relatively high costs for development and utilization. At present, the core of innovation in commercial health insurance lies in scenario-based innovation. Teams must possess the capability to build innovative scenarios and consider the alignment of needs between commercial insurance, health service providers, and cross-industry partners. This is precisely the key reason why we chose Jianyibao.”

Jianyibao has created differentiated competitive advantages for its insurance products by redesigning the cooperation models with industrial enterprises and pharmacy scenarios. As China’s consumer market has matured, numerous cross-industry institutions have accumulated large pools of precisely targeted users. Insurance companies can enhance user activity within these traffic pools, strengthen user engagement, and establish effective user benefit systems by providing incremental benefits to users. We have observed excellent user conversion results in Jianyibao’s collaborations with consumer-oriented cross-industry scenarios such as dental care and assisted reproduction, effectively empowering the healthcare service sector with high-quality traffic.

Finally, Zhao Yang expressed high expectations for future cooperation between the two parties: “For Future Capital possesses deep industrial resources in the pharmacy scenario sector and the consumer-grade market, covering more than half of China’s leading pharmacy channels. We hope to fully leverage For Future Capital’s scenario-based empowerment capabilities to assist Jianyibao in establishing the world’s largest insurance innovation platform for pharmacy scenarios, thereby providing better medical financial service products to patients.”

China Zhongji Investment Corporation Limited, established in August 2016, is a joint-stock company founded under the support of the Hebei Provincial People's Government and initiated by the Hebei Provincial Federation of Industry and Commerce, with the joint establishment of nine renowned private enterprises in Hebei Province. The company has a registered capital of RMB 10 billion. China Zhongji Investment is the provincial-level joint investment platform for private enterprises officially listed after Zhejiang Min Tou, Jiangsu Min Tou, and Guangdong Min Tou. It was initiated and established by nine shareholder units, including Rongsheng Development, Yangyuan Zhihui Beverage, and ENN Group.

For Future Capital, an industrial fund focused on healthcare innovation, counts the listed company By-Health as its cornerstone investor. It primarily invests in the migration and restructuring of the healthcare industry value chain against the backdrop of new healthcare industrial policies. Its investment focus areas include innovative healthcare payment solutions, new retail models for pharmaceuticals, innovative healthcare scenarios, and consumer-grade medical products. In November 2019, For Future Capital was awarded “Best CVC in the Industry.”